#SFHS2609114VNotice Regarding the Decision of the National Union of Health Insurance Funds Setting the Insured's Participation Rate for Pharmaceutical Products
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This decision sets a 35% participation rate for patients for specific pharmaceutical products containing methylphenidate, available in different dosages. It affects patients prescribed these medications, who will now need to cover 35% of the cost themselves.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Patients prescribed TUZULBY medications must now pay 35% of their cost.
- New participation rates apply to specific dosages: 20 mg, 30 mg, and 40 mg.
- The decision impacts those needing coverage for these specific methylphenidate products.
Obligations
What this law requires
Apply a 35% patient participation rate (co-payment) for TUZULBY 20 mg (methylphenidate hydrochloride) chewable tablets with extended release, CIP code 34009 303 333 1 0
Apply a 35% patient participation rate (co-payment) for TUZULBY 30 mg (methylphenidate hydrochloride) chewable tablets with extended release, CIP code 34009 303 333 2 7
Apply a 35% patient participation rate (co-payment) for TUZULBY 40 mg (methylphenidate hydrochloride) chewable tablets with extended release, CIP code 34009 303 333 3 4
Implement this participation rate decision effective from the date of the director general's decision (10 March 2026)